REPLICEL LIFE SCIENCES INC.

(REPCF)
Delayed OTC Markets  -  11:56 2022-06-24 am EDT
0.1005 USD   +16.59%
06/17REPLICEL LIFE SCIENCES : PROVIDES DEFAULT STATUS UPDATE - Form 6-K
PU
06/02REPLICEL LIFE SCIENCES : PROVIDES DEFAULT STATUS UPDATE - Form 6-K
PU
03/29REPLICEL LIFE SCIENCES : 51-102F3 MATERIAL CHANGE REPORT - Form 6-K
PU
SummaryQuotesChartsNewsCalendarCompanyFinancials 
 SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about REPLICEL LIFE SCIENCES INC.
06/17REPLICEL LIFE SCIENCES : PROVIDES DEFAULT STATUS UPDATE - Form 6-K
PU
06/02REPLICEL LIFE SCIENCES : PROVIDES DEFAULT STATUS UPDATE - Form 6-K
PU
03/29REPLICEL LIFE SCIENCES : 51-102F3 MATERIAL CHANGE REPORT - Form 6-K
PU
03/29REPLICEL LIFE SCIENCES : New DermaPrecise™ patent application and patents granted fo..
PU
03/22RepliCel Announces Non-brokered Private Placement
AQ
03/21RepliCel Life Sciences Inc. announced that it expects to receive CAD 1.5 million in fun..
CI
2021REPLICEL LIFE SCIENCES : 51-102F3 MATERIAL CHANGE REPORT - Form 6-K
PU
2021REPLICEL LIFE SCIENCES : Closed Final Tranche of Strategic Investment Commitment
PU
2021RepliCel Life Sciences Inc. Terminates License Agreement with Shiseido
CI
2021RepliCel Life Sciences Inc. announced that it has received CAD 0.99892 million in fundi..
CI
2021RepliCel Life Sciences Inc. announced that it expects to receive CAD 0.99892 million in..
CI
2021RepliCel Life Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Mon..
CI
2021REPLICEL LIFE SCIENCES : NOTICE OF ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS - Fo..
PU
2021REPLICEL LIFE SCIENCES : Clinical Advisory Team Delivers Skin Rejuvenation Clinical Study ..
PU
2021RepliCel Life Sciences Inc.’S Clinical Advisory Team Delivers Skin Rejuvenation Cl..
CI
More most relevant news
All news about REPLICEL LIFE SCIENCES INC.
06/17REPLICEL LIFE SCIENCES : PROVIDES DEFAULT STATUS UPDATE - Form 6-K
PU
06/02REPLICEL LIFE SCIENCES : PROVIDES DEFAULT STATUS UPDATE - Form 6-K
PU
03/29REPLICEL LIFE SCIENCES : 51-102F3 MATERIAL CHANGE REPORT - Form 6-K
PU
03/29REPLICEL LIFE SCIENCES : New DermaPrecise™ patent application and patents granted fo..
PU
03/22RepliCel Announces Non-brokered Private Placement
AQ
03/21RepliCel Life Sciences Inc. announced that it expects to receive CAD 1.5 million in fun..
CI
2021REPLICEL LIFE SCIENCES : 51-102F3 MATERIAL CHANGE REPORT - Form 6-K
PU
2021REPLICEL LIFE SCIENCES : Closed Final Tranche of Strategic Investment Commitment
PU
2021RepliCel Life Sciences Inc. Terminates License Agreement with Shiseido
CI
2021RepliCel Life Sciences Inc. announced that it has received CAD 0.99892 million in fundi..
CI
More news
News in other languages on REPLICEL LIFE SCIENCES INC.
2021RepliCel Life Sciences Inc. met fin au contrat de licence avec Shiseido
2020RepliCel en hausse de 17,5 % après la signature d'un accord sur un investissement strat..
2020REPLICEL BRIEF : En hausse de 17,5 %, les détails de la feuille de modalités contraignante..
More news
Press releases
06/17REPLICEL LIFE SCIENCES : PROVIDES DEFAULT STATUS UPDATE - Form 6-K
PU
06/02REPLICEL LIFE SCIENCES : PROVIDES DEFAULT STATUS UPDATE - Form 6-K
PU
03/29REPLICEL LIFE SCIENCES : 51-102F3 MATERIAL CHANGE REPORT - Form 6-K
PU
03/29REPLICEL LIFE SCIENCES : New DermaPrecise™ patent application and patents granted fo..
PU
03/22RepliCel Announces Non-brokered Private Placement
AQ
More press releases
Upcoming event on REPLICEL LIFE SCIENCES INC.